Chronic obstructive pulmonary disease (COPD) is both preventable and eminently treatable, yet is still the third-leading cause of death worldwide after heart disease and stroke. In this CPD-accredited webinar, Dr Alan Peter will examine the numerous combination drug trials surrounding COPD therapies and their rather interesting results. A short-acting anticholinergic plus a short-acting β-agonist (SABA) and an inhaled corticosteroid (ICS) plus a long-acting β-agonist (LABA) are among common COPD treatment combinations.

Chronic obstructive pulmonary disease (COPD) is both preventable and eminently treatable, yet is still the third-leading cause of death worldwide after heart disease and stroke [Image: Freepik].

  • DATE: 21 June 2022
  • TIME: 19:00 – 20:00
  • TOPIC: The Combination Drug Trials in COPD

DR ALAN PETER

Dr Alan Peter completed his MBBCh at Wits University. He became a Fellow of the College of Physicians of SA in 2002 and obtained a sub-specialty certificate via the same institution in 2009. He is a principal specialist as well as a physician and pulmonologist at Chris Hani Baragwanath Hospital, where he also serves as clinical head of a unit in Internal Medicine.

CLICK HERE TO REGISTER